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INTRODUCTION  
The intriguing concept that a role for estrogens exists in male reproduction has recently been 
recognized in the field of endocrinology (1, 2). It has developed from observations and 
studies that have been performed over the last 10 years. In particular, the development of 
lines of male transgenic mice lacking functional estrogen receptors or a functional aromatase 
enzyme have shed new light on the role for estrogens in male reproduction (3). 
Concomitantly, the discovery of mutations in both the human estrogen receptor alpha (4) and 
aromatase (5) genes have reinforced the idea that estrogens play a key role in the human 
male reproductive system. 
Previously a role for estrogen action in the male reproductive system was being proposed 
based on scattered data (6, 7) but recent advances have come from in vitro, in vivo and 
immunohistochemical studies which have begun to elucidate the mechanisms of estrogen 
action on the male reproductive tract (8-10). 
PHYSIOLOGY 
Estrogen biosynthesis and actions 
In males, estrogens derive from circulating androgens. Aromatization of the C19 androgens, 
testosterone and androstenedione, to form estradiol and estrone, respectively, is the key 
step in estrogen biosynthesis, which is under the control of the aromatase enzyme. The 
aromatase enzyme is a P450 mono-oxygenase enzyme complex present in the smooth 
endoplasmic reticulum which acts through three consecutive hydroxylation reactions, whose 
final effect is the aromatization of the A ring of androgens (Figure 1). P450 aromatase is the 
product of the CYP19 gene, which consists of at least 16 exons and is located on 
chromosome 15 in humans (5, 11) (Figure 2). 
Figure 1: Biochemical pathway of testosterone conversion into 
estrogen in men. 
P450 aromatase is the product of the CYP19 gene which consists of at least 16 exons and is 
located on chromosome 15 in humans (5, 11) (Figure 2). 
Figure 2: Schematic representation of the human aromatase 
gene. 
In plasma, estrogens are reversibly bound to sex hormone binding globulin (SHBG), a β-
globulin, and, to a lesser degree to albumin. Estrogen actions are mediated by binding to 
specific nuclear estrogen receptors (ERs), which are ligand-inducible transcription factors 
regulating the expression of target genes after hormone binding. Two subtypes of ERs have 
been described: estrogen receptor α (ERα) and the more recently discovered estrogen 
receptor β (ERβ). The human gene encoding for ERα is located on the long arm of 
chromosome 6, while the gene encoding for ERβ is located on band q22-24 of chromosome 
14. The two ER (α and β) proteins have a high degree of homology at the amino acid level 
(Figure 3). 
Figure 3: ERs gene and its products. 
While it is clear that estrogens regulate transcription via a nuclear interaction after binding 
their receptors, a non-genomic action of estrogens has been recently demonstrated, 
suggesting a different molecular mechanism accounts for some estrogen actions. In vitro 
studies showed a very short latency time between the administration of estrogens and the 
appearance of biological effects. These actions are thought to be mediated through cell-
surface receptors, which are not believed to act via a transcriptional mechanism (12). The 
different types of estrogen action are summarized in Table 1. 
Table 1. Estrogen actions and related biomolecular pathways and 
mechanisms. 
Estrogen 
Actions 
Receptors  Mechanism  Final effect  Features 
ERa  Transcriptional: 
nuclear 
interaction with 
estrogen-
responsive 
elements  
Modulation of 
estrogen target 
gene 
expression.  
Slow effects 
(minutes or 
hours) 
Genomic 
(nuclear 
actions)  
ERb Transcriptional: 
nuclear 
interaction with 
estrogen-
responsive 
elements  
Modulation of 
estrogen target 
gene 
expression.  
Slow effects 
(minutes or 
hours) 
Non Genomic 
(cell 
membranes 
actions)  
Estrogen 
receptors on 
cells 
membrane  
Cells 
membrane 
changes  
Changes in 
ionic transport 
through cell 
surface.  
Rapid effects 
(seconds) 
Distribution of ERs and aromatase in the male reproductive system  
ERs and the aromatase enzyme are widely expressed in the male reproductive tract in both 
animals and humans, implying that estrogen biosynthesis occurs in the male reproductive 
tract and that both locally produced and circulating estrogens may interact with ERs in an 
intracrine/paracrine and/or endocrine fashion (12). The concept of a key estrogen action in 
the male reproductive tract is strongly supported by the fact that male reproductive structures 
are able to produce and respond to estrogens (13). Here we summarize the distribution of 
both ERs and aromatase in the male reproductive tract of both animals and humans, 
accounting also for different developmental stages of maturation since both ERs and 
aromatase are widely expressed at all stages of testicular development (at least in rodents). 
ERs and aromatase in fetal rodent testis
Aromatase and ERs are found at a very early stage of development in the rodent testis, thus 
suggesting a role for estrogens in influencing testicular development (13-16, 17). 
ERα is expressed by Leydig cells in the rodent fetal testis at a developmental stage in which 
the androgen receptor is not yet expressed. The developing efferent ductules and epididymis 
also express ERα in the fetal rodent. By contrast, it is unclear whether ERα is present within 
the seminiferous tubules of the fetal testis, with variable results having been reported (13, 
16). ERα is abundant in the developing efferent ductules, which are the first male 
reproductive structures to express ERs during fetal development (18). 
ERβ is also found early in testis development in the gonocytes, Sertoli cells and Leydig cells, 
with the gonocytes showing the highest expression suggesting a role for estrogens in their 
maturation. In addition, ERβ is expressed by rat Wolffian ducts, the structures from which the 
efferent ductules and epididymis arise (13, 16). 
Aromatase is expressed in both Leydig and Sertoli cells in the rodent fetal testis, but not in 
gonocytes and immature structures of seminal tract. ERs and aromatase distribution in the 
fetal testes is summarized in Table 2. 
The finding of both aromatase and ERs in the developing fetal testis imply a possible 
involvement of estrogens in the process of differentiation and maturation of developing 
rodent testis from an early stage of morphogenesis (14, 15) (see also below: "Effects of 
estrogen excess or deficiency on male reproduction"). 
Table 2. ERs and Aromatase distribution in the rodent fetal testis. 
    ERa  ERb  Aromatase 
Leydig cells  ++  ++  + 
Sertoli cells  -  ++  ++ 
Gonocytes  -  +++  - 
Seminiferous tubules  +/-  +  + 
Ducts  +  +  - 
ERs and aromatase in postnatal immature rodent testis  
In the postnatal immature rodent testis ERα expression does not occur in the seminiferous 
epithelium, remaining confined to the Leydig cells, rete testis, efferent ductules and (13) 
epididymis (Table 3). 
In the neonatal rodent testis, ERβ is widely expressed by the rat seminiferous epithelium 
(Sertoli cells and germ cells) as well as by Leydig cells, efferent ductules and epididymis. At 
this stage ERβ seems to be the only ER in germ cells and is found in pachytene 
spermatocytes, round spermatids, and perhaps in elongated spermatids of rats and humans 
(13) (Table 3). 
Aromatase is expressed by the dividing Sertoli cells and is stimulated by FSH, with the levels 
of aromatase declining with age. Fetal Leydig cells also have the ability to produce estrogens 
in response to LH, but aromatase in this cell type is expressed to a lesser degree than during 
neonatal life. Interestingly the neonatal testis continues to show a greater degree of 
aromatase expression in the Sertoli cells than in the Leydig cells (the latter only express 
aromatase to a greater extent in the adult rat testis when they become one of the major 
sources of estrogens under the influence of LH, 13) (Table 3). Germ cells in immature rats 
do not yet express aromatase. 
Table 3. ERs and Aromatase distribution in postnatal immature rodent testis. 
    ERa ERb Aromatase 
Leydig cells +  +  + 
Sertoli cells  -  +  +++ 
Gonocytes  -  +  - 
Seminiferous tubules  -  +  + 
Ducts  +  ++  (?) 
ERs and aromatase in adult rodent testis
ERα is expressed in the Leydig cells of both adult rats and mice (19) but not in Sertoli cells. 
ERα expression in adult rodent germ cells remains to be confirmed, with its presence in 
pachytene spermatocytes and round spermatids being suggested by one study yet its 
absence demonstrated by others (see 13 for review) such that the prevailing view is that 
ERαo is absent in germ cells. Knowledge of the distribution of ERα is of great importance in 
understanding estrogen action on the male reproductive tract. ERα is highly expressed in the 
proximal reproductive ducts (rete testis, efferent ductules, proximal epididymis) and its 
expression progressively decreases distally (corpus and cauda of the epidydimis, vas 
deferens). The highest degree of ERα expression is seen in the efferent ductules of the rat 
(20) and accounts for one of the most well-documented estrogenic actions on male 
reproductive system, that of fluid reabsorption from the efferent ductules (see below in the 
text: "Role of estrogens in male reproduction"). It has to be remarked that the concentration 
of ERα in the male reproductive tract is opposite to that of ERβ, which is more concentrated 
in the distal tract (Table 4). 
Table 4. ERs and Aromatase distribution in the adult rodent testis. 
  ERa ERb Aromatase
Leydig cells  +/-  +/-  +++ 
Sertoli cells  -  +  + 
Germ cells  
Spermatogonia 
+/- 
- 
++ 
+ 
++++ 
+ (?) 
Pachytene Spermatocytes 
Round Spermatids 
Spermatozoa  
-/+ 
-/+ 
+ (?)  
+ 
+ 
+ (?)  
+ 
++ 
+ 
efferent ductules  ++++  +  - (?) 
ERβ is expressed in Leydig, Sertoli and germ cells in adult rodents (13, 16, 21, 22) and has 
also been detected in primate germ cells (23). There is now considerable evidence that germ 
cells contain both ERβ and aromatase (13, 23). It should be noted that there are some 
controversies in terms of ERβ localization, with immunohistochemical studies showing some 
discrepancies, possibly due to methodological differences (see 13 for review). It seems that 
the regulation of gonocyte multiplication, which is under the influence of growth factors and 
estradiol, may occur through the involvement of ERβ (3). 
By adulthood, rodent Leydig cells show higher aromatase activity compared to every other 
age and in comparison to Sertoli cells (24). Aromatase is also expressed at high levels in 
germ cells throughout all stages of maturation, and its expression appears to increase as the 
germ cell becomes a mature spermatid. Aromatase mRNA and activity, in fact, are found in 
germ cells from the pachytene spermatocyte stage in both rats and mice, and during their 
subsequent maturation into round spermatids (24, 25, 26, 17). Aromatase seems to be 
present in higher levels in mature spermatids of the rat than in earlier germ cells (25, 26,17). 
It is of interest that aromatase mRNA expression and enzyme activity is higher in germ cells 
when compared with Leydig cells, suggesting that germ cells may be a major source of 
estrogen in adult rodents (25, 27, 26, 17). 
When fully developed spermatids are released from the epithelium, aromatase remaining in 
the residual body is subsequently phagocyted by the Sertoli cell. Some aromatase activity 
remains in the cytoplasmic droplet that remains attached to the flagellum as the sperm make 
its way through the epididymis, suggesting that mature spermatozoa are able to synthesize 
their own estrogen as they traverse the efferent ducts (27, 28). The ability to synthesize 
estrogen gradually decreases as the droplet slowly moves to the end of the tail during 
epididymal transit until it's finally lost. The demonstration of aromatase in sperm is important 
as it suggests that the sperm itself could control the levels of estrogen present in the luminal 
fluid, directly modulating functions such as the reabsorption of fluid from the efferent ductules 
(20). 
Distribution of ERs and aromatase in the human male reproductive system
Both ERs have been found in human testis and reproductive tract. In the male fetus ERβ 
expression is higher than ERα, the latter being absent or expressed at very low levels. In the 
human fetus ERβ immunoreactivity has been shown in the seminiferous epithelium (Sertoli 
cells and a few germ cells) and in the epididymissuggesting a role for ERβ in the prenatal 
development and function of male reproductive structures (29). 
ERβ has been detected in rodent (21) as well as in primate germ cells (23). In adult men 
ERα was expressed only in Leydig cells, while ERβ .has been documented in both Leydig 
and Sertoli cells and in the efferent ducts (30). The presence of ERs in the human epididymis 
is still debated (26), even though recently ERa has been detected in the nuclei of epithelial 
cells of the caput of the epididymis (31). Both ERα and β have been detected in human 
pachytene spermatocytes and round spermatids with in situ hybridization (32, 33). These 
latter studies have been contradicted by more recent studies showing strong expression of 
ERβ in human testis but failing to find evidence for ERα using immunohistochemistry (34) 
and RT PCR (35), suggesting that ERβ is the primary mediator of estrogen action in the 
human testis. Of particular interest is the demonstration of differential expression of wild type 
ERβ (ERβ1) and a novel human variant form of ERβ, arising from alternate splicing (ERβcx, 
or ERβ2), in the human testis (36). ERβ2, which may act as a dominant negative inhibitor of 
ER action, was highest in spermatogonia and Sertoli cells in adult men, suggesting that 
these cells may be "protected" from estrogen action by the expression of this variant. 
However wild type ERβ1 was highest in pachytene spermatocytes and round spermatids, 
which have been proposed to be estrogen sensitive (see 13 for review), yet was low in less 
mature germ cells (34). 
As previously suggested by Durkee et al. (37), ERs are present in human sperm. In 
particular it has recently been documented by Luconi et al (9) that the sperm membrane 
contains an estrogen receptor-related protein able to bind steroid hormones that may act 
through a calcium-calmodulin dependent pathway and thus perhaps accounts for a well 
documented rapid non-genomic action. 
Aromatase expression in the human testis is present in both somatic and germ cells from 
pachytene spermatocytes through elongated spermatids (38, 16, 25, 39). Aromatase is also 
expressed in both human Leydig and Sertoli cells (25, 38). Recently, the presence of 
aromatase has been demonstrated not only in immature germ cells (25, 39), but also in 
mature human spermatozoa (40, 16). In contrast to rodents, aromatase expression in human 
gametes is not lost during transit through the genital tracts since P450 aromatase was 
demonstrated in ejaculated human spermatozoa at three different functional levels: mRNA 
expression (40), protein and activity (8). Thus ejaculated human spermatozoa continue to 
express P450 aromatase and contain active aromatase, and thus sperm have to be 
considered a potential site of estrogen biosynthesis (8, 25, 17). These evidences support the 
concept that human spermatozoa should be considered a mobile endocrine unit since they 
are able to synthesize and to respond to estrogens. Again, the presence of functionally 
aromatase in human spermatozoa permits the conversion of androgens into estrogens 
throughout the whole transit of reproductive tract, an event that constantly provides free 
estrogens in the seminal fluid able to act on the cells of the reproductive ducts. Recently a 
role for estrogen as survival factor during sperm transit in the seminal way has been 
suggested (33). 
In summary, the testes are able to synthesize and respond to estrogens throughout 
development. The localization of ERα, ERβ and aromatase suggests that estrogen action is 
likely to be important for testicular and efferent ductule function. The role of estrogens in the 
male reproductive system has become clearer in regard to animals, and the mapping of ERs 
and aromatase distribution in the human male reproductive system has led to the suggestion 
that estrogen plays a role in human male reproduction. As a consequence, a new field of 
research has evolved aimed at improving our knowledge of estrogen action on male 
reproduction and the molecular mechanisms involved in both animals and men. To date 
some estrogen actions on male reproduction have been well characterized but more 
research is in progress to further define the nature of estrogen action, as outlined in the 
following section. 
Role of estrogens in male reproduction 
Role of estrogens in animal male reproduction
In animals, a previously unsuspected physiological role of estrogens in testicular function 
was revealed by the creation of the ERα knockout (αERKO) mouse. Adult, sexually mature, 
male αERKO mice are infertile even though the development of the male reproductive tract 
is largely unaffected (3). Adult testicular histology shows an atrophic and degenerating 
seminiferous epithelium, together with dilated tubules and a dilation of the rete testis (41). 
The disruption of spermatogenesis is progressive as the testicular histology is normal at ten 
days of age but starts to degenerate at twenty-thirty days. By about 40-60 days the tubules 
are markedly dilated with a corresponding significant increase in testicular volume while the 
seminiferous epithelium becomes atrophic (3). A severe impairment in tubule fluid absorption 
in the efferent ducts was demonstrated to be the cause of infertility in αERKO male mice, 
and this defect is partially mimicked also by the administration of an anti-estrogen in wild-
type mice (20). In the male genital tract the highest concentration of ERα is found in the 
efferent ducts (42) and the estrogen-dependent fluid reabsorption in this site probably results 
from estrogen interaction with the ERα that seems regulate the expression of the Na(+)/H(+) 
exchanger-3 (NHE3). In fact, the disruption of ERα or the use of antiestrogens result in 
decreased expression of NHE3 mRNA, as well as in a decrease of other proteins involved in 
water reabsorption, such as aquaporin I (43, 44). The lack of fluid reabsorption in the efferent 
ductules of αERKO male mice and the consequent dilatation of these ductules induces a 
retroactive progressive swelling of the seminiferous tubules. The seminiferous tubule 
damage results from the increased fluid pressure and severely impaired spermatogenesis 
coupled with testicular atrophy as seen at the age of 150 days (20, 3). In addition, 
reproductive hormones profiles are abnormal in αERKO male mice as serum LH is 
significantly increased with a consequent elevated serum testosterone and Leydig cells 
hyperplasia, but FSH remains in the normal range (3). It is also worth noting that detailed 
investigations into the development of efferent ductules in αERKO male mice suggest that a 
congenital absence of ERα leads to developmental abnormalities in this tissue (45). 
The recent production of both aromatase knockout (ArKO, 46) and ERβ knockout (βERKO, 
47) mice supports the idea that in mice estrogen actions on the male reproductive tract are 
more complex than previously suggested on the basis of the αERKO mice (3). In fact, unlike 
αERKO mice, male ArKO mice are initially fully fertile (46), but fertility decreases with 
advancing age (48), and, conversely, βERKO mice are fully fertile and apparently 
reproductively normal in adulthood (47). 
From seven months of age male ArKO mice are not able to sire any litters. Again histology of 
the testes of one-year-old ArKO mice shows a disruption of spermatogenesis at the early 
spermatid without significant changes in the volume of seminiferous tubule lumen, together 
with Leydig cell hyperplasia (48). Despite the phenotype of αERKO male mice, the 
mechanism involved in the development of infertility is different in ArKO male mice, since the 
early arrest of spermatogenesis suggests a failure of germ cell differentiation probably 
caused by the lack of estrogen action at the level of the seminiferous epithelium rather than a 
problem referable to impaired fluid reabsorption (9, 15). Recent findings from studies in 
which human germ cells were treated with estrogen in vitro suggest that estradiol may serve 
as a survival factor for round spermatids and that lack of estradiol may promote apoptosis 
with a resulting failure in elongated spermatid differentiation (33). Recently studies in mice 
deficient in both ER α and β (αβERKO mice) showed a male phenotype very close to that of 
αERKO mice with infertility and dilated seminiferous tubules (3). These findings, together 
with the observation that βERKO male mice are fully fertile (47), lead to the hypothesis that 
estrogen activity in the male reproductive tract differs with regard to both the type of estrogen 
receptor involved in the pathway of estrogenic action and the site of action through the male 
reproductive tract. Importantly, results from mice lacking functional ERs or aromatase point 
to an important role for estrogen in the maintenance of mating behaviour in male mice, and 
that infertility in αERKO, αβERKO and ArKO mice are at least in part due to reductions in 
various aspects of mating behavior from an early age (see 3, 13 for review). 
The above studies support the concept that a functional ERα, but not ERβ, is needed for the 
development and maintenance of a normal fertility in male mice (3, 20, 41, 47). Clearly, 
further studies are needed to fully understand the precise role of estrogens and their 
receptors in the establishment and maintenance of male fertility, and the importance of 
intracrine and paracrine pathways for these effects. 
Role of estrogens in human male reproduction
The demonstration of abundant ERs in human efferent ducts and aromatase activity in 
human sperm, speaks in favor of the involvement of estrogens in male reproductive function. 
On the other hand, data from human subjects with congenital estrogen deficiency have 
provided conflicting and somewhat confusing results. The only man with estrogen resistance 
discovered up till now, a human equivalent of the ERKO mouse, had normal testicular 
volumes and a normal sperm count but with slightly reduced motility (4) (Table 5). The four 
adult men affected by congenital aromatase deficiency showed a variable degree of impaired 
spermatogenesis ( 49, 50, 51, 52, 53). The patient described by Carani et al., showed both a 
severely reduced sperm count and an impairment of sperm viability with germ cell arrest at 
the level of primary spermatocytes (5, 14, 49) (Table 5). A more recent patient had complete 
germ cell arrest on testicular biopsy but a semen analysis was not performed according to 
patient's religious views ( 50, 51) (Table 5). Data concerning the patient described by 
Morishima et al. are lacking since sperm counts were not analyzed (52) (Table 5). It should 
be remarked that a clear cause-effect relationship between infertility and aromatase 
deficiency is not demonstrable in the patient studied by Carani et al., since one of his 
brothers was infertile despite the absence of mutations in the aromatase gene, suggesting 
an alternate common cause for their infertility. (49). 
Recently a new patient with aromatase deficiency has been described to have impaired 
fertility (53), confirming a possible association between congenital estrogen deficiency and 
infertility. 
Table 5: Reproductive phenotypes of men with congenital estrogen 
deficiency. 
SUBJECTS  REPRODUCTIVE 
HORMONES  
EXTERNAL 
GENITALIA  
SEMEN 
ANALYSIS 
Estrogen 
resistance (Age: 
28 yrs)  
(ref 5)  
Increased serum 
LH. 
Increased serum 
FSH. 
Normal serum 
testosterone. 
Increased serum 
estradiol.  
Normal male 
genitalia. 
 
Volume of each 
testis:20-25 mL.  
Sperm count: 
25x106 / mL 
(normal >  20 x 106 
/ mL). 
Viability: 18% 
(normal > 50%). 
Aromatase 
deficiency (Age: 
24 yrs)  
(refs 52 and 68)  
Increased serum 
LH. 
Increased serum 
FSH. 
Increased serum 
testosterone. 
Undetectable 
serum estradiol.  
Normal male 
genitalia.Volume of 
each testis: 34 mL  
Not performed. 
Aromatase 
deficiency (Age: 
38 yrs)  
Normal-to-raised 
serum 
LH.Increased 
Normal male 
genitalia.Volume of 
each testis: 8mL.  
Sperm count: 1x 
106 / ml (normal > 
20 x 106 / mL). 
(refs 49 and 125)  serum FSHNormal 
serum 
testosterone. 
Undetectable 
serum estradiol.  
Viability: 0% 
(normal > 50%).  
Testis biopsy: germ 
cell arrest at 
primary 
spermatocyte level.
Aromatase 
deficiency (Age: 
28 yrs)  
(refs 50 and 51)  
Normal serum LH. 
Increased serum 
FSH. Low-normal 
serum 
testosterone. 
Undetectable 
serum estradiol.  
Cryptorchidism. 
Volume of each 
testis: 10-11 mL.  
Not performed. 
Testis biopsy: 
complete germ cell 
arrest. 
Aromatase 
deficiency (Age: 
27 yrs)  
(ref 53)  
Normal serum LH 
Increased serum 
FSH 
Increased serum 
testosterone 
Undetectable 
serum estradiol  
Volume of each 
testis: 13-14 mL  
Sperm count: 17.4 
x 106 / ml (normal 
>20 x 106 / mL). 
Viability: reduced 
The variable degree of fertility impairment in men with congenital deficiency of estrogen 
action or synthesis deficiency does not permit a firm conclusion about whether these 
features are a consequence of a lack of estrogen action or are only epiphenomena, even 
though a possible role of estrogen on human spermatogenesis is suggested by rodent 
studies. Recently, the administration of aromatase inhibitors to infertile men with an impaired 
testosterone to estradiol ratio resulted in an improvement of fertility rate (10), although in the 
absence of a placebo or control group, these findings need to be interpreted with great 
caution. Clearly our knowledge of a role for estrogen in human male reproduction is far from 
complete. The exposure to the excess of environmental estrogens has been proposed as a 
possible cause of impaired fertility. It is difficult to reconcile existing data about effects of both 
estrogen deficiency and excess on male reproductive function (1, 6, 54, 55, 56). These 
issues are discussed further below. 
Regulation of gonadotropin feedback 
The regulation of gonadotropin feedback is an important and well-documented action of 
estrogen in males. While testosterone has been classically considered the key hormone for 
the control of gonadotropin feedback in the male (Figure 4), a role for estrogens has become 
clear from studies performed in normal and GnRH-deficient men. Recently, the discovery of 
men with congenital estrogen deficiency has also provided further evidence for the 
relationship between estrogens and gonadotropin secretion in men (5). 
Figure 4: Traditional knowledge concerning sex steroids on the 
control of gonadotropin secretion. 
 
The effects of estrogens on gonadotropin secretion have been investigated in GnRH 
deficient males whose gonadotropin secretion was normalized by pulsatile GnRH 
administration. In order to determine the precise role of sex steroids in the hypothalamo-
pituitary-testicular axis, two studies were performed in which testosterone alone, 
testosterone plus testolactone (an aromatase inhibitor), or estradiol were administered (57, 
58). When given testosterone alone, these subjects revealed a significant decrease in mean 
basal LH and FSH levels as well as LH pulse amplitude, demonstrating a direct suppressive 
effect on the pituitary of testosterone and its metabolites. Mean LH levels and LH frequency 
were suppressed to a greater extent in normal control subjects during testosterone 
administration suggesting also a hypothalamic site of action of testosterone in suppressing 
GnRH secretion. In order to discriminate the impact of testosterone as opposed to its 
aromatized products, both groups of subjects were administered with testosterone plus 
testolactone. The addition of the aromatase inhibitor completely prevented the suppression 
of gonadotropin secretion by testosterone in both normal and GnRH deficient men: in fact the 
mean LH levels increased significantly in both groups. The increase in mean LH levels was 
greater in the normal men who received testolactone alone compared to normal men who 
received testosterone plus testolactone, thus revealing also a direct effect of androgens in 
normal men. 
It is clear that the aromatization of testosterone into estradiol is required for normal 
gonadotropin feedback at the pituitary level (57). In fact, when the same experimental model 
was applied using estradiol administration, mean LH and FSH levels as well as LH pulse 
amplitude all decreased significantly during estradiol administration (58). This study 
demonstrates an important direct inhibitory effect of estradiol on gonadotropin secretion in 
both the GnRH-deficient and normal men ( 57, 58) and supports the concept that at least 
part of the inhibitory effect on gonadotropin secretion is mediated by the conversion of 
testosterone to estradiol (52, 53). In contrast it seems that the 5α-reduction of testosterone to 
DHT does not play an important role in pituitary secretion of gonadotropins (59). 
More recently a hypothalamic site of action of estrogens has been demonstrated in men. In 
order to clarify the role of estrogen on the feedback regulation of gonadotropin secretion at 
the hypothalamic level, Hayes et al (60) conducted a study involving the administration of the 
aromatase inhibitor, anastrozole, to men affected by idiopathic hypogonadotropic 
hypogonadism (IHH), whose gonadotropin secretion had been normalized by long term 
pulsatile GnRH therapy. They observed that inhibition of estradiol synthesis led to an 
increase in mean gonadotropin levels in both normal and IHH men, but with a greater 
increase in the normal subjects suggesting a hypothalamic mode of action. The rise in mean 
LH levels in the normal subjects was shown to be due to anastrozole causing an increase in 
LH pulse frequency and amplitude. The authors concluded that estrogen acts at the 
hypothalamic level to decrease both GnRH pulse frequency and pituitary responsiveness to 
GnRH (60). 
Accordingly, the effects of estrogen on gonadotropin secretion at the pituitary level has 
recently been demonstrated to operate from early- to mid-puberty (61, 62) into old age in 
men (63). The administration of an aromatase inhibitor (anastrozole 1 mg daily for 10 weeks) 
to boys aged 15-22 years (61) resulted in a 50% decrease in serum estradiol concentrations, 
an increase in testosterone concentrations and an increase in both LH and FSH values 
during the whole study protocol. These hormonal parameters returned to normal values after 
discontinuation of anastrozole treatment. Recently, administration of letrozole, another potent 
aromatase inhibitor, was shown to increase serum LH, frequency of LH pulse amplitude and 
the response of LH to GnRH administration in boys during early and mid-pubertal phases, 
indicating that estrogens acts at the pituitary level during early phases of puberty (62). The 
same mechanism continues to operate during adulthood and also during early senescence. 
In fact, in fifteen eugonadal men aged 65 years treated with 2 mg anastrozole for 9 weeks, 
serum FSH and LH levels increased significantly, in spite of an increase in serum 
testosterone levels (63). 
Data suggests that estradiol may modulate GnRH receptors number and function at the 
pituitary level (64), although no ERs, (at least of the α type) were found in GnRH secreting 
neurons in monkeys (65). However ERβ is found in GnRH expressing neurons in male and 
female rats (66). The precise mechanism of estrogen action at both the hypothalamic and 
pituitary level in men remains unclear (67). It remains to be established whether estrogen 
receptors are involved at these two sites and/or whether non-genomic estrogen actions play 
a role in the control of the gonadotropin feedback. Further studies are needed to establish 
the contribution of both circulating and locally produced estrogens to gonadotropin feedback 
as well as the target cells involved in estrogen action within the hypothalamus. Nevertheless 
it is now well established that some androgens need to be converted to estrogens in order to 
ensure the integrity of the gonadotropin feedback mechanism in men, testosterone itself 
having a more minor role than previously thought (Figure 5). 
Figure 5: Sex steroids control of gonadotropin secretion after 
recent advances. 
Our understanding of the role of estrogens in gonadotropin feedback has been enhanced 
through studies of men affected with congenital estrogen deficiency. The description of a 
man lacking a functional ERα (4) revealed a remarkable hormonal pattern consisting of a 
normal serum testosterone, high estradiol and estrone levels but increased serum FSH and 
LH concentrations (Table 5). Other important information about the role of estrogens in the 
human male has come from the discovery of naturally occurring mutations in the aromatase 
gene. To date five different cases of human male aromatase deficiency have been 
described, four of these males were discovered to be aromatase deficient during adulthood 
and one as a child (49-53, 68, 69). The four adult patients had an increase in basal FSH 
concentrations, while LH showed a more heterogeneous pattern, being elevated only in one 
subject (52, 68), high to normal in another (49, 70, 71) and normal in the third and fourth (50, 
51, 53). Serum testosterone concentrations were also variable being elevated (52, 53, 68), 
normal (49, 70, 71) and low to normal (50, 51) in the four patients respectively. In all four 
patients estradiol concentrations were undetectable (Table 5). The demonstration of elevated 
gonadotropin levels in the presence of normal to increased serum testosterone levels in 
these men further highlights the important role for estrogen in regulating circulating 
gonadotropins in men. 
A detailed study of the effects of different doses of transdermal estradiol on pituitary function 
in a man with congenital aromatase deficiency demonstrated that estrogens might control not 
only basal secretion of gonadotropins but also their responsiveness to GnRH administration. 
In this study, estrogen administration to a male patient with aromatase deficiency resulted in 
a decrease in both basal and GnRH-stimulated LH, FSH and a-subunit secretion with the 
response to GnRH administration being dose-dependent (71) (Figure 6). These results have 
been recently confirmed in the last case of aromatase deficiency described (53). However, a 
complete normalization of serum FSH during estradiol treatment was not achieved in the 
presence of physiological levels of circulating estradiol and supraphysiological levels of 
estrogens were necessary to obtain FSH normalization (49, 70), however this was attributed 
to the concomitant severe impairment of patient's spermatogenesis. 
Figure 6: Basal and stimulated serum LH levels in a man 
affected with aromatase deficiency: effect of three different 
dosages of transdermal estradiol. (TE) (66) 
Some difficulties remain with interpreting these data from men with congenital estrogen 
deficiency. For example, in the young patient with congenital aromatase deficiency, no 
abnormalities were found in either gonadotropin secretion nor in testis size; both testes were 
descended and the penis was normal (69). The presence of normal levels of gonadotropins 
raises the possibility that the role of estrogens in the hypothalamo-pituitary-testicular axis 
only become relevant in a later stage of life than infancy. Thus the control of gonadotropin 
feedback exerted by sex steroids during early infancy and childhood remains a matter of 
debate in the human male. 
Clinical and therapeutical implication
On the basis of the certain role of estrogens on gonadotropic feedback inhibition (72, 73, 74), 
some clinical insights on the management of male infertility have been made. 
Since 1960s antiestrogen agents have been used as an empirical treatment of male infertility 
(75), based on their modulation of the hypothalamic-pituitary testicular axis. The blockade of 
the negative feedback on gonadotrophins, in fact, which is obtained by the inhibition of 
estrogen action at hypothalamic and pituitary levels, excites LH and FSH secretion with a 
proposed consequent stimulatory effect on spermatogenesis, in the absence of clear 
evidence of direct effects of antiestrogens on spermatogenesis (74, 76, 77, 78). Accordingly, 
LH and FSH serum levels increase after aromatase inhibitor administration in infertile men 
(79 (79). 
Clomiphene or tamoxifen have been the most used antiestrogen agents for the treatment of 
male infertility (77, 78, 80, 81, 82, 83); on the contrary the new generation of selective 
estrogen receptor modulators does not show significant changes in male fertility (84, 85). 
Tamoxifen represents the first line treatment for men affected by idiopathic oligozoospermia 
as recommended by WHO (2000) (76). However, the real efficacy of antiestrogens is far 
from being elucidated yet since other works (80, 81) provided opposite conflicting results (77, 
82). Besides, it is a matter of debate whether the increase of sperm density induced by 
antiestrogens is actually related to a real improvement of both sperm fertility and pregnancy 
rate (78, 83). A possible explanation of uncertain results for what concerns antiestrogen 
efficacy in the treatment of male infertility is that patients with idiopathic oligozoospermic 
constitute an heterogeneous group, of which only a subgroup responds positively to therapy 
(86, 87). However till now all the studies failed to identify the characteristics of this subgroup 
and now physicians still do not know in advance who will improve sperm count during 
treatment and differences between responder and non-responder (86, 87). 
Tamoxifen (20 mg/d) has been also used with testosterone undecanoate (120 mg/day) in 
men affected by idiopathic oligozoospermia. This combined treatment was efficacious in 
improving not only the sperm parameters (total sperm number, sperm morphology and 
motility) (82, 88), but also the pregnancy rate (88). 
Few data are available about the effect of aromatase inhibitors in male infertility. A previous 
study failed in demonstrating the efficacy of testolactone in the treatment of idiopathic 
oligozoospermic infertility. However, when aromatase inhibitors (testolactone or anastrazole) 
are administered in a selected group of infertile men with abnormal baseline testosterone-to-
estradiol ratio an improvement of fertility rate is obtained (10). 
In conclusion antiestrogens, alone or in combination with testosterone, may represent a first 
line therapy for idiopathic oligozoospermia, as suggested by WHO, before using assisted 
reproduction techniques. However, further studies will be necessary to detect the real 
efficacy of antiestrogens treatment in improving the pregnancy rate or to identify the features 
of the responders to treatment.  
EFFECTS OF EXCESS ESTROGEN OR ESTROGEN DEFICIENCY ON 
MALE REPRODUCTION 
Exposure to excess estrogens in animals 
In order to evaluate the effect of estrogen excess on the reproductive tract, several studies 
have been performed in various animal species treated with diethylstilbestrol, a synthetic 
estrogenic compound. In male mice, the critical period for Műllerian duct formation is day 13 
post-coitus. Prenatal exposure of fetal male mice to DES caused a delay in Műllerian duct 
formation by approximately two days as well as incomplete Műllerian duct regression with a 
female-like differentiation of the non-regressed caudal part (89). An increase in the 
expression of anti-Műllerian-Hormone (AMH) mRNA in male mice fetuses exposed to DES 
has also been demonstrated. This increase was not accompanied by a regression of the 
ducts. This data was interpreted to suggest that the asynchrony in the timing of Műllerian 
duct formation, with respect to the critical period of Műllerian duct regression, led to the 
persistence of Műllerian duct remnants at birth in male mice. Moreover DES exposure did 
not impair embryonal genetic development, but increased ERs number, and slightly 
prolonged the gestation time (cesarean sections were performed to rescue the litter and 
revealed no difference in size of fetuses from control and DES treated mothers). The timing 
of DES exposure is crucial to the induction of abnormalities of Műllerian duct development 
and regression (89). 
Many studies in rodents suggest that inappropriate exposure to estrogen in utero and during 
the neonatal period impairs testicular descent, efferent ductule function, the hypothalamic-
pituitary-gonadal axis, and testicular function (see 2 and 13 for review). The latter effect can 
be a direct consequence of exposure to excess estrogen, as well as a secondary effect due 
to perturbations in circulating hormones or the ability of the efferent ductules to reabsorb 
fluid. Some studies show that low dose estrogenic substances given during puberty can 
actually stimulate the onset of spermatogenesis, likely due to stimulatory effects on FSH 
(90), highlighting the fact that the effects of excess estrogen on male fertility are often 
complex. The effects of excess estrogen in the neonatal period can impact upon the testis 
into adulthood, with permanent changes in testis function and spermatogenesis evident (see 
2 and 13 for review). 
Aromatase over-expression in rodents
Recently a transgenic line of mice overexpressing aromatase enzyme (AROM+) has been 
developed (91, 92). These mice show highly elevated serum estradiol concentrations, with a 
reciprocal decrease in testosterone concentrations. The AROM+ males display several of the 
changes observed in males perinatally exposed to estrogens, such as undescended testes, 
testicular interstitial cell hyperplasia, hypoandrogenism, and growth inhibition of accessory 
sex glands. A disruption of spermatogenesis has also been observed which could be a 
consequence of multiple factors, including cryptorchidism, abnormal Leydig cell function, 
hypoandrogenemia or hyperestrogenemia. Estrogens are thought to inhibit Leydig cell 
development, growth and function, resulting in the suppression of androgen production (see 
13 for review). The observation of numerous degenerating germ cells and the absence of 
spermatids within the seminiferous tubules of AROM+ mice suggest that germ cells 
development was arrested at the pachytene spermatocyte stage in the cryptorchid testes. 
Interestingly, the spermatogenic arrest occurred at a stage where P450arom is typically 
expressed. The spermatogenic arrest found in the AROM+ mice could be explained, at least 
partially, by the suppression of FSH action. The reduced serum FSH levels in AROM+ males 
are further evidence of the inhibiting actions of estrogens on FSH secretion in males. No 
significant differences in the LH concentrations were seen in AROM+ and wild type mice (91, 
92). 
Exposure to excess estrogens in humans 
The clinical use of diethylstilbestrol (DES) by pregnant women in order to prevent 
miscarriage resulted in an increased incidence of genital malformations in their sons (93). In 
these individuals the presence of Műllerian ducts remnants was found indicating that fetal 
exposure to DES may have an effect on sex differentiation in men, as is the case in rodents 
(89). Moreover a large number of structural and functional abnormalities were found, the 
most frequent being: epididymal cysts, meatal stenosis, hypospadias, cryptorchidism and 
microphallus (93). The frequency of abnormalities was dependent on the timing of estrogen 
exposure: in fact, men who were exposed to DES before 11th week of gestation (i.e. the time 
of Műllerian ducts formation) had a two fold higher rate of abnormalities than those who were 
exposed only later (93). This data supports the previously discussed hypothesis that the 
asynchrony between formation and regression of embryonal reproductive structures is 
determined by estrogen exposure. 
Various reports have demonstrated that semen quality of men exposed to DES in utero is 
significantly worse than in unexposed controls (94, 95). However, the sperm concentrations 
of most of the DES exposed men were well above the limit at which subfertility occurs, and it 
is therefore not surprising that the fertility of these men was reported to be normal (7). The 
risk of testicular cancer among men exposed to DES in utero has been a controversial issue 
and several meta-analyses showed no increased risk (96). However more direct evidence 
will be necessary in order to fully understand this issue. 
While various studies suggest that environmental estrogens affect male fertility in animal 
models, the implications for human spermatogenesis are less clear (97). It has been 
demonstrated that male mice whose mothers have consumed a 29 ng/g dose of bisphenol A 
for seven days during pregnancy had a 20% lower sperm production as compared to control 
males (98). Various abnormalities in reproductive organs have also been described in males 
exposed to bisphenols (i.e. a significant decrease in the size of the epididymis and seminal 
vesicles and an increase in prostate gland volume), suggesting that bisphenols interfere with 
the normal development of the Wolffian ducts in a dose-related fashion. Exogenous 
estrogens could interfere with the development of the genital structures if administered 
during early organogenesis, by leading to both an impairment of gonadotropin secretion and 
by creating an imbalance in the androgen to estrogen ratio, which may account for impaired 
androgen receptor stimulation or inhibition according to the dose, the cell type and age (93, 
99, 100, 101). 
An excess of environmental estrogens has been suggested as a possible cause of impaired 
fertility in humans (54, 55, 56). A progressive decline in sperm count has been reported in 
some Western countries during the past 50 years, suggesting a possible negative effect of 
environmental contaminants on male reproductive function (6, 55, 93, 99). Data concerning 
the role of estrogens in male reproductive structure development remains conflicting. Animal 
studies suggest that exposure to estrogen excess may negatively affect the development of 
reproductive male organs. These effects, however, are considered to be the result of an 
impaired hypothalamic-pituitary function as a consequence of estrogen excess and of the 
concomitant androgen deficiency (100, 101). Much of the knowledge on excess estrogen 
exposure and human fertility depends upon animal data and the validity of these concepts to 
humans has not been established. 
Aromatase over-expression in humans
In 1996 a boy with aromatase excess syndrome was reported (102). His condition was 
presumably inherited in an autosomal dominant fashion with sex-limited expression as his 
father had a history of peripubertal gynecomastia, elevated serum estrogen levels and 
increased aromatase activity in vitro. The father was fertile and had a normal libido despite a 
small testicular volume (15 mL bilaterally), and a reduced testosterone level of 234 ng/dL 
(102). In the son, mild suppression of testicular growth and Leydig cell function probably 
reflected direct estrogen negative feedback on pituitary gonadotropin secretion. In general, 
the inhibitory effects of estrogen on reproductive function appear to be milder in males with 
aromatase excess syndrome than in patients receiving exogenous estrogens or with 
estrogen-secreting tumors, probably because serum estradiol and/or estrone levels are lower 
in the former (102). 
Estrogen deficiency: animal models 
The study of transgenic mice lacking ERs or the aromatase enzyme demonstrated that a 
lack of estrogen was compatible with life and represented an interesting model to evaluate 
the physiology of estrogen in males. Congenital estrogen deficiency in mice leads to an 
impairment of male reproductive function to a variable degree, ranging from normal fertility 
with a fully male phenotype in βERKO mice to complete infertility in both αERKO and 
αβERKO mice. An intermediate pattern exists for the ArKO mice in which spermatogenesis 
is normal in young mice, but is progressively impaired during aging (3, 13, 20, 41, 46-48, 
103, 104). 
These data have been just described in detail in a previous section (see up in the text: "Role 
of estrogens in male reproduction") and are now only summarized (Table 6). 
Table 6: Male mouse models of estrogen deficiency. 
aERKO  bERKO  abERKO  ArKO 
Infertility (41)  Fully fertile (47)  Similar to aERKO 
mice (3)  
Normal fertility in 
young mice, 
infertility with 
advancing age (46)
Normal FSH 
Elevated LH 
Elevated 
testosterone 
Elevated estradiol  
- 
- 
- 
-  
- 
- 
- 
-  
Normal FSH 
Elevated LH 
Elevated 
testosterone 
Undetectable 
estradiol 
Germ cell 
deprivation with 
dilated 
seminiferous 
tubules  
Normal testicular 
histology  
Testicular histology 
similar to aERKO 
mice  
Histology of the 
testis is disrupted 
with advancing age
Impairment of 
sexual behavior  
Normal sexual 
behavior  
Complete 
suppression of 
sexual behavior  
Impairment of 
sexual behavior 
The testes of infertile αERKO male mice show significant atrophy of the seminiferous 
epithelium and severe dilation of the tubule lumen. Interestingly these defects aren't present 
at birth, but they progressively become evident as the testicular phenotype of these mice 
worsens (3). When germ cells from αERKO mice are transplanted in wild type mice, they 
show a normal development (105). The αERKO mouse is also characterized by a reduced 
number, motility and fertilizing capacity of the sperm. The βERKO mice have normal testes 
and normal sperm count and they are fertile (see 3 for review).  
Recently, the creation of ArKO mice has permitted to clarify the effects of the lack of 
estrogens on male reproductive function. Morphological studies revealed a progressive 
disruption of spermatogenesis at one year of age, with a concomitant impairment of sperm 
count and motility (46, 48). 
The function of the hypothalamo-pituitary-testicular axis is impaired in both αERKO and 
ArKO male mice, leading to elevated serum LH levels in presence of normal values of FSH, 
while, as expected, testosterone is augmented and estrogens are higher than normal or 
undetectable in αERKO and ArKO mice, respectively (3, 13). Thus negative effects on male 
reproduction are the result of estrogen deprivation directly in the reproductive structures or 
indirectly through changes in the regulation of sex steroid secretion. 
It remains to be ascertained if congenital estrogen deficiency affects the development of 
male reproductive structures. In fact, even though the negative effects of excess estrogen 
exposure during fetal life are well documented, mouse models with congenital estrogen 
deficiency show normal male reproductive structure, suggesting that congenital estrogen 
deficiency does not alter the development of male reproductive tract in animals (3, 13). It 
should be noted that some defects in the development of the efferent ductules in αERKO 
mice are thought to be a consequence of a congenital absence of estrogen action (45). 
Estrogen deficiency is not associated with abnormalities of testicular descent in transgenic 
mouse models. However, in αERKO male mice a defect in cremaster muscle development 
has been demonstrated (106), whereas ArKO mice developed normally, likely as a 
consequence of the presence of circulating maternal estrogens during fetal life (46, 48). 
Estrogen deficiency: human models 
Effect of estrogen deficiency on gonadotropin feedback
The role of estrogens in human male physiology has become better understood as a result of 
the description of a man lacking a functional estrogen receptor alpha (4). This patient 
presented with tall stature, continuing linear growth during adulthood, unfused epiphyses and 
osteoporosis. He had normal serum testosterone, high estradiol and estrone levels, and 
increased FSH and LH concentrations. He had normal male genitalia with bilaterally 
descended testes each of 20-25 mL volume and a normal prostate volume. No further 
studies were performed on the reproductive system of this male (Table 5). The only data 
available are those on sperm characteristics, which revealed a reduced viability of sperm 
(Table 5). 
Other important information about the role of estrogens in the human male came from the 
discovery of naturally occurring mutations in the aromatase gene. To date only five different 
cases of human male aromatase deficiency have been found, four of these males were 
discovered to be aromatase deficient during adulthood and one of them as a child (49-53, 
68, 69,). 
The hormonal pattern of the four adult patients affected by aromatase deficiency is 
summarized in Table 5. The study of men with aromatase deficiency shows that estrogens 
modulate gonadotropin feedback by regulating both basal secretion of gonadotropins and 
their responsiveness to GnRH (49, 53, 68, 70, 71). 
In the young patient with congenital aromatase deficiency no alterations were found either in 
gonadotropin secretion or in testis size, both testes were descended and the penis was 
normal (69). The presence of normal levels of gonadotropins raises the possibility that the 
role of estrogens in the regulation of the hypothalamo-pituitary-testicular axis becomes 
relevant in a later stage of life than infancy. This is in contrast to aromatase deficient female 
patients in whom an elevation of FSH and LH is seen even in childhood (107), demonstrating 
the importance of estrogens in the feedback regulation of gonadotropin secretion in girls 
during every stage of life. 
Effect of estrogen deficiency on the human testis
Two of the adult males affected by aromatase deficiency showed a decreased testicular 
volume, one had normal testes, while the other had large testes. The histological study 
performed in only two of the four patients showed profound alterations in germ cell 
development, in particular one of the two patients had germ cells arrest at primary 
spermatocytes and the other had complete depletion of germ cells. Sperm analysis of one of 
these two patients showed severe oligozoospermia and astenozoospermia (Table 5). It 
remains unclear as to whether their disordered estrogen physiology accounts for the 
spermatogenic defects. 
Effect of estrogen deficiency on the development of reproductive structures
Bilateral cryptorchidism was present in one patient with aromatase deficiency (50, 51), 
suggesting a possible role of estrogen also in testis descent, although this was not seen in 
the transgenic mice models (see above). The presence of a unique case of cryptorchidism 
among men with aromatase deficiency does not permit any conclusions to be drawn 
concerning a possible relationship between estrogen deficiency and the occurrence of 
abnormalities in testis development and descent. 
ESTROGEN AND MALE SEXUAL BEHAVIOR 
Gender-identity and sexual orientation 
Sex steroids and particularly testosterone are able to affect adult male sexual behavior in 
mammals (108). In non-primate mammals, androgen exposure during late fetal and early 
neonatal development in the male accounts for the sexual dimorphism of the central nervous 
system (CNS), probably as a result of testosterone aromatization in the brain (109-114). 
Prenatal and perinatal estrogen action in the brain is believed to be responsible for the 
establishment of a male brain (115). Paradoxically, male rat brain is exposed to a greater 
amount of estradiol than female brain, since ovaries release less estrogen than testes at this 
stage of development (obviously in male estrogens derives from the conversion of 
testosterone produced by testis). Furthermore, estrogens are inactivated in the female fetus 
by various biochemical mechanisms, such as binding to alpha-fetoprotein (116). As a 
consequence, a sexual dimorphism of hypothalamic structures develops in rodents and the 
same mechanism seems to be involved also for the establishment of differences in 
hypothalamic structures between men and women (114, 117-119). 
The role of sex steroids and of testosterone aromatization in the determination of the 
imprinting of sexual behavior has been considered of primary importance for the 
determination of both adult sexual orientation and sexual behavior in both animals and 
humans (114, 118-120). It was suggested a possible role of prenatal hormonal exposure on 
sexual orientation (113, 121) also on the basis of some differences in hypothalamic 
structures which have been found between heterosexual and homosexual men (117, 121). In 
particular, prenatal androgen deficiency and the lack of its estrogenic metabolites was 
proposed? to be responsible for male homosexuality (113, 122). In fact, the lack of estrogen 
action on the developing brain, in males, was believed to be strictly related to both 
dimorphism of hypothalamic structures, and sexual orientation development (113, 117, 121, 
122).  
Recently, the concept of a possible role of estrogen on sexual orientation and gender identity 
arise from the demonstration that the aromatase expression in the hypothalamus, the volume 
of hypothalamic nuclei, and partner preference are associated in animals (123). 
Anyhow data concerning a possible strict linkage among anatomic correlates, prenatal and 
perinatal hormonal exposure, and sexual orientation in humans have been widely criticised 
(124) and debated (122).  
Aromatase deficiency in men accounts for the absence of aromatase activity in the brain 
during prenatal and perinatal period, constituting a unique experimental model to study the 
role of estradiol on human male sexual behavior modulation. 
Recently, a detailed study of a man with aromatase deficiency did not reveal any 
abnormalities of both gender-identity and sexual orientation (125). Based on this study the 
patient was categorized as masculine, his gender identity was male and the psychosexual 
orientation was heterosexual. Also data from the other men with aromatase deficiency don't 
show any association between congenital aromatase deficiency and gender-identity or 
sexual orientation disturbances (4, 50-53, ,) (Table 7). Since aromatase deficient patients 
would be subjected to maternal estrogens in utero, it is also possible that such estrogen 
exposure would be sufficient for sexual behavior development. 
These data suggest that congenital aromatase deficiency does not affect psychosexual 
orientation and gender-identity in humans and that, in contrast to animals, human 
psychological and social factors may be the most relevant determinants of gender role 
behavior in men, with hormones having a minor role. Hormones, in fact, may affect sexual 
differentiation and sex assignment at birth and, only indirectly, psychosexual development in 
men (101). 
Table 7: Sexual behavior in men with congenital estrogen and aromatase 
deficiency. 
SUBJECTS  SEXUAL FUNCTION  GENDER 
IDENTITY  
PSYCHOSEXUAL 
ORIENTATION 
Estrogen 
resistance (Age: 
28 yrs)  
(ref 5)  
Libido: normal. 
Morning erections: normal. 
Nocturnal emissions: 
normal. 
Ejaculations: normal.  
Male  Heterosexual 
Aromatase 
deficiency (Age: 
24 yrs)  
(refs 52 and 68)  
Libido: modest. Morning 
erections: normal. 
Nocturnal emissions: 
normal. Ejaculations: 
normal.  
Male  Heterosexual 
Aromatase 
deficiency(Age: 
38 yrs) 
(refs 49 and 125)  
Libido: normal. 
Morning erections: normal. 
Ejaculations: normal.  
Male  Heterosexual 
Aromatase 
deficiency (Age: 
28 yrs)  
(refs 50 and 51)  
Morning erections: normal. 
Libido and sexual activity 
have not been investigated 
according to the religious 
Male  Heterosexual 
thinking of the patient. 
Aromatase 
deficiency (Age: 
27 yrs)  
(ref 53)  
Libido: normal. 
Morning erections: normal. 
Ejaculations: normal.  
Male  Heterosexual 
Sexual behavior  
In mammals, adult male sexual behavior is at least partially dependent on the presence of 
testosterone. Androgens are also necessary for male sexual behavior during adult life (126-
128). In fact, the lack of testosterone frequently produces loss of libido and erectile 
dysfunction (127, 128). At the same time, testosterone replacement therapy increases sexual 
interest and improves sexual behavior (108, 127). By contrast, the role of aromatization in 
the establishment and maintenance of male sexual behavior has been characterized only 
recently. 
Congenital aromatase deficiency and estrogen action blockade result in a severe impairment 
of sexual behavior in rodents. ArKO mice (46) exhibit a significant reduction in mounting 
frequency and a significantly prolonged latency to mount when compared with heterozygous 
and wild-type animals (129). Also the sexual behavior of αERKO mice is characterized by a 
reduction of intromissions, an increase in the latency to first intromission and a lack of 
ejaculation, despite the presence of a normal motivation to mount females. The same sexual 
behavior pattern occurs in αβERKO male mice (see 3, 13 for review). On the contrary, 
βERKO mice showed all three components of sexual behavior including ejaculation (Figure 
7). These findings suggest that at least one of the ERs (ERα) is required for the expression 
of simple mounting behavior in male mice and, as a consequence, that activation of the 
androgen receptor alone is not sufficient for a fully normal sexual behavior, confirming that 
aromatization of androgens is also required.  
However, novel evidence suggests that this issue may be more complex than expected. 
Genetic background may affect sexual behavior in some lines of inbreeded α-knock out 
mice. Accordingly, some selected genetic backgrounds restored sexual behavior (particularly 
intromission and ejaculation) in αERKO mice offspring (130). 
Figure 7: Sexual behavior in estrogen deficient male mice. 
The role of estrogens in male sexual behavior is confirmed by studies in gonadectomized 
rats treated with testosterone (131). Vagell and McGinnis showed, in fact, a complete 
inhibition of male sexual behavior in gonadectomized rats when the aromatase inhibitor 
fadrozole was administered in addition to testosterone, demonstrating that this inhibition 
disappeared when estrogen administration was added (131). 
Much less is known about the role of estrogens in sexual behavior in the human male, 
particularly the degree to which the effects of testosterone ought really be ascribed to its 
conversion into estradiol. Previous studies aimed at addressing this issue have provided 
conflicting results both in support (132, 133) and against (134, 135) an important role of 
estrogen on human male sexuality. In order to evaluate the role of estrogens in human male 
sexual behavior, sexual activity has been investigated in a man with aromatase deficiency, 
before and during testosterone or transdermal estradiol treatment. When the patient received 
his physiological dose of estrogens (i.e. 25 μg transdermal estradiol twice weekly) he 
experienced an increase of all the parameters of sexual activity (the frequency of 
masturbation, sexual intercourse, erotic fantasies and libido) (Table 7, Figure 8), without 
change during testosterone treatment. Recently, sexual behavior was investigated in one of 
the other three men with aromatase deficiency (51). In this patient, also affected by 
hypogonadism, sexual function was unaffected by testosterone or estradiol treatment alone, 
while the associated treatment induced a great increase in libido, in frequency of 
masturbation and in sexual fantasies with a concomitant normalization of testosterone and 
estradiol serum levels (51)  
In men with congenital estrogen deficiency it seems that estrogen may play a role in adult 
sexual behavior, even if it's not possible to exclude that the improvements observed were the 
result of an improvement in well being and mood related to the estrogen replacement 
therapy. Recently, estrogen receptors have been identified in the corpus cavernosum 
suggesting also a possible involvement of estrogen in the local mechanism of erection (136). 
Thus, a possible indirect effect of testosterone through the activation of the aromatase 
pathway may be possible also in the penile tissue. This is confirmed by data obtained in 
rodent in which reproductive behaviour is severely impaired when estrogen action is absent 
(3, 129, 137). 
Figure 8: Sexual behavior parameters in a men with aromatase deficiency: 
effect of testosterone and estradiol treatment.  
• PHASE A: before testosterone treatment.  
• PHASE B: during testosterone treatment (testosterone enanthate): 250 
mg every 10 days i.m for 6 months.  
• PHASE C: before estradiol treatment.  
• PHASE D: during transdermal estradiol treatment: 50 mg twice/week 
transdermal estradiol for 6 months.  
• PHASE E: during transdermal estradiol treatment: 25 mg twice/week 
transdermal estradiol for 9 months.  
• PHASE F: during transdermal estradiol treatment: 12,5 mg twice/week 
transdermal estradiol for 9 months.  
These findings from transgenic mice and humans deficient in aromatase suggest that 
physiological levels of estrogens could be required for completely normal sexual behavior. 
CONCLUSIONS 
Sex steroids account for sexual dimorphism because they are responsible for the 
establishment of primary and secondary sexual characteristics, which are under the control 
of androgens and estrogens in male and female, respectively (Figure 9). 
 
Figure 9: Direct and indirect (estrogen-mediated) testosterone 
action. 
Advances in the understanding of the role of estrogens in animal and human models suggest 
a role for this sex steroid in the reproductive function of both sexes. The fact that both 
estrogen excess and estrogen deficiency influence male sexual development, testis function, 
the hypothalamic-pituitary-testis axis, spermatogenesis and ultimately male fertility highlight 
the importance of estrogen action in the male. From an evolutionary perspective this 
provides an example of the parsimony operating in biological events that are crucial for the 
evolution of the human species such as growth and reproduction. 
This chapter has been concerned with the reproductive effects of estrogens in males but 
there are emerging roles for estrogens in non-reproductive tissues. In particular, while 
traditionally, testosterone has been considered the sex hormone involved in bone maturation 
and growth arrest in men, but recently the key role of estrogens on growth has been 
emphasised (5, 49). In men and women, in fact, epiphyseal closure and growth arrest are not 
achieved without estrogens, underlining the fact that estrogens on human growth are highly 
conserved in both sexes. Thus it is clear that testosterone might act directly or through its 
conversion into estrogens (124). This aspect of estogen action is discussed in Chapter 2 and 
Chapter 3 in this section.  
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